Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ACME Laboratories's Enterprise Value is BDT38,645 Mil.
ACME Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was BDT4,986 Mil. Therefore, ACME Laboratories's EV-to-EBIT ratio for today is 7.75.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ACME Laboratories's Enterprise Value is BDT38,645 Mil.
ACME Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT5,561 Mil. Therefore, ACME Laboratories's EV-to-EBITDA ratio for today is 6.95.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, ACME Laboratories's Enterprise Value is BDT38,645 Mil.
ACME Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was BDT30,463 Mil. Therefore, ACME Laboratories's EV-to-Revenue ratio for today is 1.27.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
ACME Laboratories (DHA:ACMELAB) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
ACME Laboratories's current Enterprise Value is BDT38,645 Mil.
ACME Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT4,986 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
ACME Laboratories's current Enterprise Value is BDT38,645 Mil.
ACME Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT5,561 Mil.
ACME Laboratories's current Enterprise Value is BDT38,645 Mil.
ACME Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT30,463 Mil.
ACME Laboratories's current Enterprise Value is BDT38,645 Mil.
ACME Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT4,186 Mil.
ACME Laboratories's current Enterprise Value is BDT38,645 Mil.
ACME Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT2,463 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories Enterprise Value Related Terms
ACME Laboratories Enterprise Value Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Enterprise Value distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
ACME Laboratories's Enterprise Value for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of BDT38,645 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a Enterprise Value of BDT38,645 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ACME Laboratories and its competitors.
Is ACME Laboratories' Enterprise Value too high?
ACME Laboratories' current Enterprise Value is BDT38,645 Mil. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Enterprise Value compare to ZTS and UTHR?
ACME Laboratories' Enterprise Value of BDT38,645 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ACME Laboratories and its competitors. ACME Laboratories's current Enterprise Value is BDT38,645 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.08, compared to a current price of BDT82.60 — trading 34% below its estimated fair value. The current Enterprise Value is BDT38,645 Mil. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Enterprise Value is BDT38,645 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT82.60 is trading 34% below its estimated GF Value™ of BDT125.08.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Enterprise Value: BDT38,645 Mil
GF Value™: BDT125.08 vs. price of BDT82.60 (34% below fair value)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
